Human variation in CYP-specific chlorpyrifos metabolism

Toxicology

Volumn 276, Issue 3, 2010, Pages 184-191

  Croom, Edward L ^a   Wallace, Andrew D ^a   Hodgson, Ernest ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Chlorpyrifos; CYP isoform; Dearylation; Desulfuration; Human liver microsomes; Organophosphorothioate pesticides

Indexed keywords

3,5,6 TRICHLORO2 PYRIDINOL; CHLORPYRIFOS; CHLORPYRIFOS OXON; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 C19; KETOCONAZOLE; TICLOPIDINE; TOXIN; UNCLASSIFIED DRUG; CYP2B6 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; INSECTICIDE; ISOENZYME; N DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PHENOTYPE; PRIORITY JOURNAL; TOXICOGENETICS; ANIMAL; CELL LINE; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; LIVER MICROSOME; METABOLISM; PHYSIOLOGY; TOXICITY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE; CHLORPYRIFOS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INSECTICIDES; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; SUBSTRATE SPECIFICITY; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C19;

EID: 77957287125     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.08.005     Document Type: Article

References (35)

1. Baldwin S.J., Bloomer J.C., Smith G.J., Ayrton A.D., Clarke S.E., Chenery R.J. Ketoconazole and sulfaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995, 25:261-270.
2. Buratti F.M., Leoni C., Testai E. Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides. Toxicol. Lett. 2006, 167:245-255.
3. Buratti F.M., Volpe M.T., Meneguz A., Vittozzi L., Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol. Appl. Pharmacol. 2003, 186:143-154.
4. CFR (Code of Federal Regulations), 2006. Appendix B to Part 136-Definition and procedure for the determination of the method detection limit-Revision 1.11, Electronic Code of Federal Regulations, Title 40, February 2006.
5. Chambers H.W. Organophosphorus compounds: an overview. Organophosphates: Chemistry, Fate, and Effects 1992, 3-17. Academic Press, San Diego, CA. J.E. Chambers, P.E. Levi (Eds.).
6. Cole T.B., Walter B.J., Shih D.M., Tward A.D., Lusis A.J., Timchalk C., Richter R.J., Costa L.G., Furlong C.E. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genomics 2005, 15:589-598.
7. Croom E.L., Stevens J.C., Hines R.N., Wallace A.D., Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem. Pharmacol. 2009, 78:184-190.
8. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W., Goldstein J.A. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 2001, 299:825-831.
9. Eaton D.L., Daroff R.B., Autrup H., Bridges J., Buffler P., Costa L.G., Coyle J., McKhann G., Mobley W.C., Nadel L., Neubert D., Schulte-Hermann R., Spencer P.S. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit. Rev. Toxicol. 2008, 38:1-125.
10. EPA, 2001. U.S. EPA. Chlorpyrifos. Revised Risk Assessment and Agreement with Registrants. U.S. Environmental Protection Agency, Office of Pesticide Programs, Washington, DC.
11. Eyer F., Roberts D.M., Buckley N.A., Eddleston M., Thiermann H., Worek F., Eyer P. Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochem. Pharmacol. 2009, 78:531-537.
12. Ferguson S.S., Chen Y.P., LeCluyse E.L., Negishi M., Goldstein J.A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4 alpha. Mol. Pharmacol. 2005, 68:747-757.
13. Foxenberg R.J., McGarrigle B.P., Knaak J.B., Kostyniak P.J., Olson J.R. Human hepatic cytochrome P450-specific metabolism of parathion and chlorpyrifos. Drug Metab. Dispos. 2007, 35:189-193.
14. Hofmann M.H., Blievernicht J.K., Klein K., Saussele T., Schaeffeler E., Schwab M., Zanger U.M. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 2008, 325:284-292.
15. Hoppin J.A., Umbach D.M., London S.J., Lynch C.F., Alavanja M.C.R., Sandler D.P. Pesticides associated with wheeze among commercial pesticide applicators in the Agricultural Health Study. Am. J. Epidemiol. 2006, 163:1129-1137.
16. Howard A.S., Bucelli R., Jett D.A., Bruun D., Yang D.R., Lein P.J. Chlorpyrifos exerts opposing effects on axonal and dendritic growth in primary neuronal cultures. Toxicol. Appl. Pharmacol. 2005, 207:112-124.
17. Itoh K., Inoue K., Yanagiwara S., Kyoya H., Suzuki T. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biol. Pharm. Bull. 1999, 22:77-79.
18. Lee S.J., Bell D.A., Coulter S.J., Ghanayem B., Goldstein J.A. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J. Pharm. Exp. Ther. 2005, 313:302-309.
19. Lee S.J., Lee S.S., Jeong H.E., Shon J.H., Ryu J.Y., Sunwoo Y.E., Liu K.H., Kang W., Park Y.J., Shin C.M., Shin J.G. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab. Dispos. 2007, 35:2095-2101.
20. Levin E.D., Addy N., Baruah A., Elias A., Christopher N.C., Seidler F.J., Slotkin T.A. Prenatal chlorpyrifos exposure in rats causes persistent behavioral alterations. Neurotoxicol. Teratol. 2002, 24:733-741.
21. Lu C.S., Barr D.B., Pearson M.A., Waller L.A. Dietary intake and its contribution to longitudinal organophosphorus pesticide exposure in urban/suburban children. Environ. Health Perspect. 2008, 116:537-542.
22. Miksys S., Lerman C., Shields P.G., Mash D.C., Tyndale R.T. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003, 45:122-132.
23. Mutch E., Williams F.M. Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology 2006, 224:22-33.
24. Richter T., Murdter T.E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M., Zanger U.M. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 2004, 308:189-197.
25. Rodrigues A.D. Integrated cytochrome P450 reaction phenotyping - attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 1999, 57:465-480.
26. Sachana M., Flaskos J., Sidiropoulou E., Yavari C.A., Hargreaves A.J. Inhibition of extension outgrowth in differentiating rat C6 glioma cells by chlorpyrifos and chlorpyrifos oxon: effects on microtubule proteins. Toxicol. In Vitro 2008, 22:1387-1391.
27. Sams C., Cocker J., Lennard M.S. Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 2004, 34:861-873.
28. Stevens J.C., Hines R.N., Gu C.G., Koukouritaki S.B., Manro J.R., Tandler P.J., Zaya M.J. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 2003, 307:573-582.
29. Tang J., Cao Y., Rose R.L., Brimfield A.A., Dai D., Goldstein J.A., Hodgson E. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab. Dispos. 2001, 29:1201-1204.
30. Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., Kuwahara T., Shirasaka T., Kimura S., Oka S. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 2004, 319:1322-1326.
31. Usmani K.A., Cho T.M., Rose R.L., Hodgson E. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab. Dispos. 2006, 34:1606-1614.
32. Usmani K.A., Rose R.L., Hodgson E. Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. Drug Metab. Dispos. 2003, 31:384-391.
33. Whyatt R.M., Camann D., Perera F.P., Rauh V.A., Tang D., Kinney P.L., Garfinkel R., Andrews H., Hoepner L., Barr D.B. Biomarkers in assessing residential insecticide exposures during pregnancy and effects on fetal growth. Toxicol. Appl. Pharmacol. 2005, 206:246-254.
34. Williams M.K., Barr D.B., Camann D.E., Cruz L.A., Carlton E.J., Borjas M., Reyes A., Evans D., Kinney P.L., Whitehead R.D., Perera F.P., Matsoanne S., Whyatt R.M. An intervention to reduce residential insecticide exposure during pregnancy among an inner-city cohort. Environ. Health Perspect. 2006, 114:1684-1689.
35. Xenotech, 2008. Donor Information for Human Liver Microsomes.